3D3C3AAA-2C7A-43C6-8137-73A6E0896FAC
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.708
- TNFA_SIGNALING_VIA_NFKB+0.638
- INTERFERON_GAMMA_RESPONSE+0.605
- ANGIOGENESIS+0.601
- IL6_JAK_STAT3_SIGNALING+0.598
- INFLAMMATORY_RESPONSE+0.560
- INTERFERON_ALPHA_RESPONSE+0.548
- MTORC1_SIGNALING+0.547
- ALLOGRAFT_REJECTION+0.520
- MYC_TARGETS_V1+0.517
Top 10 suppressed
- KRAS_SIGNALING_DN-0.391
- SPERMATOGENESIS-0.292
- HEDGEHOG_SIGNALING-0.111
- MYOGENESIS-0.067
- PANCREAS_BETA_CELLS-0.058
- MITOTIC_SPINDLE-0.048
- WNT_BETA_CATENIN_SIGNALING+0.008
- BILE_ACID_METABOLISM+0.084
- APICAL_SURFACE+0.093
- FATTY_ACID_METABOLISM+0.147
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | F9EB85A8-8E6D-44C0-8C59-50B1DB4E652B | — | — | 0.987 |
| 2 | 5307FA7F-DFE5-42BC-BFC7-826AACAAE799 | — | — | 0.983 |
| 3 | E9FC1686-028B-476C-B51B-4956213D874B | — | — | 0.977 |
| 4 | F9A39954-57EB-4A3F-97A0-1801B08BBD53 | — | — | 0.976 |
| 5 | A219A5D7-C67B-4CF0-860A-78ADEB56A13D | — | — | 0.973 |
| 6 | 25C4D537-0142-4DAA-874B-BC793336DE82 | — | — | 0.972 |
| 7 | AA762299-102B-4E35-B4A5-A94A122EF9DB | — | — | 0.971 |
| 8 | D8A3D7E7-BDC0-42FF-B451-E25F472E8612 | — | — | 0.971 |
| 9 | 825AC0F8-4D16-4109-AA6A-4648934E3C35 | — | — | 0.970 |
| 10 | 18D7DFBC-A1C6-4DA8-9AF1-3A6F3E2A03BE | — | — | 0.970 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 44 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.708 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.638 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.605 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.601 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.598 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.560 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.548 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.547 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.520 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.517 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.505 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.505 | Idelalisib | — uncovered |
| APOPTOSIS | 0.502 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.467 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.457 | Inavolisib | — uncovered |
| HYPOXIA | 0.448 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.441 | Idelalisib | — uncovered |
| COMPLEMENT | 0.440 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.435 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.433 | Idelalisib | — uncovered |